258. Patti G, B rczi G, Orlic D, et al. Outcome comparison of 600- and 300- mg loading doses of clopidogrel in patients undergoing primary per- cutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial In- farction) randomized study. J Am Coll Cardiol. 2011;58:1592 9. 259. Mehta SR, Tanguay J-F, Eikelboom JW, et al. Double-dose versus stan- dard-dose clopidogrel and high-dose versus low-dose aspirin in individu- als undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233 43. 260. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001 15. 261. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circu- lation. 2010;122:2131 41. 262. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double- blind, randomised controlled trial. Lancet. 2009;373:723 31. 263. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 pa- tients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005; 95:1218 22. 264. Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardio- vascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379 86. 265. Brener SJ, Barr LA, Burchenal JE, et al; for the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. 